NCT01558362View on ClinicalTrials.gov

A Study of 123I-CMICE-013 Radiopharmaceutical in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Coronary Artery Disease
Interventions
DRUG

123I-CMICE-013

2 intravenous doses of drug will be given one week apart. Doses will be equivalent to 1 rest dose and 1 stress dose. Serial nuclear imaging will follow dose injections. All volunteers had a rest dose first followed by a stress dose.

Trial Locations (1)

K1Y 4W7

University of Ottawa Heart Institute, Ottawa

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Ottawa Heart Institute Research Corporation

OTHER

NCT01558362 - A Study of 123I-CMICE-013 Radiopharmaceutical in Healthy Volunteers | Biotech Hunter | Biotech Hunter